Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
|25 Mar 2021||$1.1500||0.00%||Interim||20 Apr 2021|
|19 Sep 2019||$1.7500||100.00%||Final||14 Oct 2019|
|25 Mar 2019||$1.5500||100.00%||Interim||16 Apr 2019|
|17 Sep 2018||$1.6000||100.00%||Final||10 Oct 2018|
|19 Mar 2018||$1.4000||100.00%||Interim||12 Apr 2018|
|19 Sep 2017||$1.4000||100.00%||Final||11 Oct 2017|
|15 Mar 2017||$1.3000||100.00%||Interim||06 Apr 2017|
|07 Sep 2016||$1.2000||100.00%||Final||29 Sep 2016|
|10 Mar 2016||$1.1000||100.00%||Interim||01 Apr 2016|
|08 Sep 2015||$1.0000||100.00%||01 Oct 2015|
|03 Mar 2015||$0.9000||35.00%||26 Mar 2015|
|02 Sep 2014||$1.2700||20.00%||Final||25 Sep 2014|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Cochlear Limited (COH) is a global leader in implantable hearing devices. The company manufactures and distributes cochlear implantable devices for hearing impaired.
Based in Sydney, Cochlear has operations in more than 20 countries, distributing its products in America, Asia Pacific, Europe, the Middle East and Africa. It offers three main products: Cochlear implants, Baha bone conduction implants and Cochlear Wireless Accessories.
Cochlear was formed in 1981, with COH shares first listing on the ASX almost 15 years later in 1995. Since then, the Cochlear share price has risen exponentially and the company is now one of the largest-listed companies on the ASX.
|17 Sep 2021||$238.28||$0.16||0.07%||246,631||$240.20||$240.37||$237.00|
|16 Sep 2021||$238.12||$3.40||1.45%||175,860||$237.98||$239.47||$234.61|
|15 Sep 2021||$234.72||$4.72||2.05%||124,405||$231.00||$236.36||$229.22|
|14 Sep 2021||$230.00||$-1.20||-0.52%||124,840||$231.54||$234.36||$227.52|
|13 Sep 2021||$231.20||$-1.52||-0.65%||108,571||$233.48||$234.82||$229.58|
|10 Sep 2021||$232.72||$-4.00||-1.69%||132,647||$238.88||$239.95||$232.01|
|09 Sep 2021||$236.72||$-2.52||-1.05%||105,295||$239.00||$240.20||$235.50|
|08 Sep 2021||$239.24||$-4.45||-1.83%||149,616||$243.00||$244.38||$238.71|
|07 Sep 2021||$243.69||$4.80||2.01%||280,711||$239.27||$244.60||$238.89|
|06 Sep 2021||$238.89||$1.53||0.64%||132,714||$234.85||$238.89||$231.00|
|03 Sep 2021||$237.36||$4.82||2.07%||157,037||$233.20||$238.49||$233.16|
|02 Sep 2021||$232.54||$1.24||0.54%||126,138||$232.79||$234.08||$228.43|
|01 Sep 2021||$231.30||$-1.90||-0.81%||95,594||$232.28||$232.85||$229.56|
|31 Aug 2021||$233.20||$4.44||1.94%||180,849||$229.50||$234.83||$229.06|
|30 Aug 2021||$228.76||$1.91||0.84%||105,796||$226.86||$229.50||$226.20|
|27 Aug 2021||$226.85||$-1.44||-0.63%||167,621||$225.35||$227.28||$222.62|
|26 Aug 2021||$228.29||$-0.93||-0.41%||115,419||$229.22||$230.49||$226.60|
|25 Aug 2021||$229.22||$-7.47||-3.16%||188,964||$238.00||$238.00||$229.02|
|24 Aug 2021||$236.69||$-4.86||-2.01%||161,305||$241.47||$241.97||$236.69|
|23 Aug 2021||$241.55||$4.50||1.90%||156,847||$236.88||$242.45||$236.37|
|20 Aug 2021||$237.05||$-19.04||-7.43%||322,200||$241.00||$244.83||$236.15|
|19 Aug 2021||$256.09||$2.10||0.83%||88,307||$252.02||$257.76||$251.14|
|07 Sep 2021||Dig Howitt||Sell||8||$2,132,934||
|03 Sep 2021||Dig Howitt||Exercise||8||$1,823,734||
Exercise of options.
|03 Sep 2021||Dig Howitt||Buy||8||$1,823,734||
Exercise of options.
|25 Aug 2021||Christine McLoughlin||Buy||232||$53,617||
|23 Aug 2021||Dig Howitt||Cancelled||1||$305,319||
Cancellation of securities. 9,214 - Performance Rights
|23 Aug 2021||Dig Howitt||Buy||3||$737,935||
Conversion of securities.
|23 Aug 2021||Dig Howitt||Cancelled||26||$6,501,559||
Cancellation of securities.
|23 Aug 2021||Dig Howitt||Exercise||3||$737,935||
Conversion of securities. 10,478 - Performance Rights
|23 Aug 2021||Christine McLoughlin||Buy||168||$40,671||
|26 Feb 2021||Catriona Deans||Buy||786||$163,825||
|21 Oct 2020||Dig Howitt||Issued||4||$1,062,703||
Issue of securities. 13,533 - Performance Rights
|21 Oct 2020||Dig Howitt||Issued||21||$4,715,053||
Issue of securities.
|Ms Christine Frances McLoughlin||Non-Executive Director||Nov 2020||
Ms McLoughlin has served on the boards of a number of ASX50 companies and is a company director with domestic and international experience in financial and health services and telecommunications. She has had ranging experience covering health, insurance, resources, infrastructure and financial services. She is currently Chairman of the Suncorp Group Limited, Chancellor-elect of the University of Wollongong, and is a non-executive director of nib holdings limited.
|Mr Michael Grenfell Daniell||Non-Executive Director||Jan 2020||
Mr Daniell has worked in the medical device industry for 40 years and has executive leadership experience. He was Managing Director and CEO of Fisher & Paykel Healthcare Corporation Limited ("Fisher & Paykel Healthcare") from November 2001 to March 2016. Prior to this, Mr Daniell held various technical management and product design roles within Fisher & Paykel Healthcare. Mr Daniell is currently a Non-Executive Director of Fisher & Paykel Healthcare. He is also a Council Member of the University of Auckland and a Non-Executive Director of the Medical Research Commercialisation Fund in Melbourne, Australia. He is also member of Nommination.
|Ms Catriona Alison Deans||Non-Executive DirectorNon-Executive Chairman||Jan 2015||
Ms Deans is a company director with experience across a range of industries. During her executive career she held leadership roles as a CEO, strategic advisor and technology investor, including CEO of venture capital firm netus, CEO of technology investment firm ecorp, and was the first CEO of eBay Australia. While a consultant with McKinsey in London and Sydney, she focused on client issues related to innovation and growth. Ms Deans is currently Chair of the Technology & Innovation Committee and a member of Risk and People & Culture Committees of Cochlear. Ms Deans is also serving on the boards of Ramsay Health Care Ltd and Deputy Group Pty Ltd, and on the Investment Committee of MainSequence Ventures (Manager of the CSIRO Innovation Fund). She was formerly on the boards of Insurance Australia Group Limited, Westpac Banking Corporation, ecorp Pty Ltd and Social Ventures Australia.
|Mr Andrew Leslie Denver||Non-Executive Director||Feb 2007||
Mr Denver is the member of the Medical Science, Technology & Innovation Committees. He has experience in the life sciences industry. He was the Managing Director of Memtec Limited and President Asia for Pall Corporation. He is the Chairman of SpeeDx and Director, Vaxxas and QBiotics.
|Ms Yasmin Anita Allen||Non-Executive Director||Aug 2010||
Ms Allen is a member of the People & Culture, Technology & Innovation Committees. He has a career in investment banking with senior roles in strategic analysis and corporate advice. She was Former Vice President of Deutsche Bank AG. She is the Director, Santos Limited, ASX Limited and National Portrait Gallery, Member of the George Institute for Global Health Board. She is also Chairman, Advance (Global Australian Network) and Acting President, Australian Government Takeovers Panel. he was Director, Insurance Australia Group Limited, National director of the Australian Institute of Company Directors; Member of The Salvation Army Advisory Board; Chair of Macquarie Specialised Asset Management; Director, ANZ Investment Bank and Associate Director, HSBC London.
|Mr Glen Francis Boreham||Non-Executive Director||Jan 2015||
Mr Boreham is the Chairman of the People & Culture Committee, Member of the and Technology & Innovation Committees. He led organisations in information technology, new media and the creative industries through periods of rapid change and innovation. Former Managing Director of IBM Australia and New Zealand. He is also Director, Southern Cross Media Group and Link Group. Chairman, Advisory Board IXUP. He was Director of Data#3. Chairman of Screen Australia, Advance (Global Australian Network), Business School and Industry Advisory Board for the University of Technology, Sydney. He is also the member of Audit & Risk committee.
|Professor Bruce Gregory Robinson||Non-Executive Director||Dec 2016||
Professor Robinson is the Chairman of Medical Science Committee, member of the People & Culture and Technology & Innovation Committees. He has over 20 years leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. He was former Dean, The University of Sydney's Sydney Medical School, Head of Medicine at Sydney's Royal North Shore Hospital and Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research. He is the Chairman, National Health and Medical Research Council and Medical Benefits Schedule Review Taskforce, Director, MaynePharma and QBiotics. He is also member of Nomination Committee.
|Mr Dig Howitt||PresidentChief Executive OfficerManaging Director||Jul 2017||
Mr Howitt has experience across the Company in roles including Chief Operating Officer, SVP, Manufacturing and Logistics and President, Asia Pacific. Prior to joining Cochlear, he worked for Boral and Boston Consulting Group. He is a member of the Medical Science and Technology & Innovation Committees
|Mr Ray Jarman||Company Secretary||Feb 2017||
|Ray Jarman||Company Secretary||
|HSBC Custody Nominees (Australia) Limited||28,405,386||43.24%|
|J P Morgan Nominees Australia Pty Limited||11,371,030||17.31%|
|Citicorp Nominees Pty Limited||4,113,509||6.26%|
|National Nominees Limited||1,682,907||2.56%|
|BNP Paribas Noms Pty Ltd <DRP>||1,540,107||2.34%|
|BNP Paribas Nominees Pty Ltd <Agency Lending DRP A/C>||1,132,094||1.72%|
|HSBC Custody Nominees (Australia) Limited GSCO ECA||738,643||1.12%|
|Australian Foundation Investment Company Limited||323,715||0.49%|
|HSBC Custody Nominees (Australia) Limited (NT Comnwlth Super CORP)||300,693||0.46%|
|Netwealth Investments Limited <Wrap Services A/C>||231,860||0.35%|
|Citicorp Nominees Pty Limited <Colonial First State INV A/C>||226,944||0.35%|
|Mr Christopher Graham Roberts||162,173||0.25%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <DRP A/C>||103,774||0.16%|
|PGA (Investments) Pty Ltd||100,118||0.15%|
|National Nominees Limited <DB A/C>||86,230||0.13%|
|AMP Life Limited||79,421||0.12%|
|HSBC Custody Nominees (Australia) Limited A/C 2||71,519||0.11%|
|UBS Nominees Pty Ltd||70,592||0.11%|
|Avanteos Investments Limited <Encircle IMA A/C>||68,964||0.10%|
|Custodial Services Limited <Beneficiaries Holding A/C>||67,214||0.10%|
Cochlear typically pays twice yearly dividends in April and October. Over the past five years, the company’s dividends have all been fully franked. Prior to this, Cochlear’s dividends varied between fully franked and partially franked with only one dividend over this time being 100% unfranked. Cochlear’s last interim dividend of $1.60 per share was paid on 17 April 2020. The medical devices company has an impressive dividend payment history dating back to 1997. In March 2020, however, Cochlear withdrew its FY20 earnings guidance and announced a capital raising to enhance its liquidity. This was following the negative impacts of COVID-19 on its revenue streams. It also announced suspension of the company’s dividend until trading conditions improve.
At at 17 June 2020, Cochlear does not offer a dividend reinvestment plan.